Maxim Group downgraded ADMA Biologics (NASDAQ: ADMA) from Buy to Hold after the company received a Complete Response Letter (CRL) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE